Skip to main content
. 2022 May 16;11(10):1649. doi: 10.3390/cells11101649

Figure 1.

Figure 1

Human STIP1 ameliorates staurosporine-induced neurotoxicity in human dopaminergic neurons derived from induced pluripotent stem cells. Neurons were pre-treated with STIP1 over 1 h prior to staurosporine treatment over 16–20 h. Cell viability was quantified using the MTS assay and bar graphs are represented as the mean ± standard error of mean (SEM) percentage of cell death normalised against untreated neurons for each condition. (A) Primary mouse hippocampal neurons were treated with 1 μM mouse STIP1 followed by 31.25 nM staurosporine treatment. (B) Human induced pluripotent stem cells (hiPSCs) derived dopaminergic neurons from healthy (blue) and Parkinson’s disease (red) individuals were treated with 1 μM human STIP1 followed by 250 nM staurosporine. All experiments were independently repeated two to four times. Paired t-test analysis was performed for all samples except for the primary mouse hippocampal neurons, which was analysed using an unpaired t-test. * p < 0.05, ** p < 0.01.